Specialty Pharmaceutical Company with a Focus in Pain and Addiction

BioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2018 Healthcare Conference

November 16, 2018

RALEIGH, N.C., Sept. 25, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that Herm Cukier, Chief Executive Officer will present at two upcoming healthcare conferences:

Cantor Fitzgerald Global Healthcare Conference 2018
Date:  Monday, October 1, 2018
Presentation Time:  4:05 PM Eastern Time
Location:  InterContinental New York Barclay Hotel, New York City, NY

Ladenburg Thalmann 2018 Healthcare Conference
Date:  Tuesday, October 2, 2018
Presentation Time:  3:00 PM Eastern Time
Location:  Sofitel New York, New York City, NY

The presentations will be webcast live and can be accessed at www.bdsi.com.  For those who are not available to listen to the live broadcast, replay of the webcasts will be available on the BDSI website.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain.  BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain and opioid dependence.  BDSI's headquarters is in Raleigh, North Carolina.  

For more information, please visit or follow us:

Internet: www.bdsi.com
Facebook: Facebook.com/BioDeliverySI
Twitter: @BioDeliverySI

BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) and BELBUCA® (buprenorphine) buccal film (CIII) are marketed in the U.S. by BioDelivery Sciences.  For full prescribing information and important safety information on BDSI products please visit www.bdsi.com where the Company promptly posts press releases, SEC filings and other important information or contact the Company at (800) 469-0261.  For full prescribing and safety information on BELBUCA, please visit www.belbuca.com and for full prescribing and safety information on BUNAVAIL, please visit www.bunavail.com.

© 2018 BioDelivery Sciences International, Inc.  All rights reserved.

Contacts
Mary Coleman
Vice President, Investor and Public Relations
BioDelivery Sciences International, Inc.
919-582-9050
mcoleman@bdsi.com

Monique Kosse
Managing Director
LifeSci Advisors
212-915-3820
monique@lifesciadvisors.com

dumb client is dumb.jpg

Source: BioDelivery Sciences International, Inc.